MAAT INDEX

CLAIM #48548 · Pfizer Inc (PFE) · 2025Q1 earnings call · Apr 29, 2025 · due Dec 31, 2025

We expect total company full-year 2025 revenues to be in the range of $61 to $64 billion

David Denton · CFO

PENDING
graded after results covering Dec 31, 2025 are reported

In context

pe, shaped by rapidly evolving trade and tariff policies. Our functional team is analyzing a range of potential outcomes while developing strategies to help us mitigate the potential impact on our business in both the short as well as the long term. These actions include the management of current inventory levels in certain jurisdictions, leveraging our domestic manufacturing footprint, and the potential production of certain API and products in the US. Should we be impacted by further tariffs in the future, we will assess the impact of these policies enacted and provide information at the appropriate time. Let me now spend just a few minutes on our 2025 guidance, which remains unchanged. To be clear, it does not include the potential impact of future changes in trade and tariff policies. We expect total company full-year 2025 revenues to be in the range of $61 to $64 billion, and full-year 2025 adjusted diluted earnings per share to be in the range of $2.80 to $3.00 a share, which reflects our expectation of strong contributions across our product portfolio and our focused discipline on cost management. As we finish Q1 with earnings strength, and excluding the potential impact related to future trade changes, we are currently trending towards the upper end of our adjusted diluted earnings per share guidance range. In closing, let me emphasize several key aspects of our business. We will continue our focus on executing to maximize the commercial value of our product portfolio. We remain committed to driving value-creating innovation while strengthening our pipeline. Additionally, our cost improvement programs are set to deliver operating margin expansion. Expe

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2025Q1 earnings call.